FindTrial
Sign In

To see immunohistochemistry marker positivity in patients with oral cavity cancer in a hospital set up for better understanding of the cancer and plan the best treatment accordingly.

Expression of p16 and ALK on Immunohistochemistry in patients with oral cavity squamous cell carcinoma in a tertiary care hospital - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075913
Enrollment
80
Registered
2024-10-25
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

Intervention1: Not Applicable: Not Applicable

Sponsors

Dr Shuvankar Srutikar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All the histopathologically diagnosed case of Squamous Cell Carcinoma of oral cavity

Exclusion criteria

Exclusion criteria: 1.Insufficient material on tissue block for Immunohistochemistry 2.Already treated cases and relapse cases of oral cavity squamous cell carcinoma

Design outcomes

Primary

MeasureTime frame
Proportion of HPV in oral cavity squamous cell carcinoma (OSCC) specimens as indicated by p16 immunohistochemistry positivityTimepoint: Baseline—

Secondary

MeasureTime frame
ALK overexpression as a marker to identify Oral cavity Squamous Cell Carcinoma patientsTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr SP Sinhasan

All India Institute of Medical Sciences Guwahati

spsinhasan@aiimsguwahati.ac.in9442551998

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026